4 completed, 3 active not recruiting, 2 terminated, 1 recruiting. 11 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Active not recruiting 3, Terminated 2, Recruiting 1, Unknown 1 |
| Phase 3 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Cystadenocarcinoma: new trials by email Literature Review of Cystadenocarcinoma trials Research Report on Cystadenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer Pembrolizumab - Ovarian Cancer, Low Grade Serous Carcinoma | Phase 2 | Active not recruiting | North Eastern German Society of Gynaecological Oncology | 33 | 2022-02-22 | 2026-10-02 |
| A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma Azenosertib - Uterine Serous Carcinoma | Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 92 | 2021-07-28 | 2026-03-18 |
| Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma Niraparib - Endometrial Carcinoma, Serous Carcinoma | Phase 2 | Recruiting | Shandong University | 83 | 2021-06-01 | 2024-01-05 |
| A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy - Endometrial Carcinoma, P53 Mutation | Phase 2 / Phase 3 | Terminated | University Health Network, Toronto | 11 | 2020-11-17 | 2025-08-12 |
| Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) Platinum-Based Drug, Conventional chemotherapy - Ovarian Cancer, Ovarian Neoplasms | Phase 2 / Phase 3 | Unknown | Blokhin's Russian Cancer Research Center | 164 | 2019-09-01 | 2019-08-13 |
| Ribociclib and Letrozole Treatment in Ovarian Cancer Ribociclib, Letrozole - Low Grade Serous Carcinoma | Phase 2 | Active not recruiting | Gynecologic Oncology Group | 51 | 2019-05-20 | 2025-12-23 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 260 | 2014-04-11 | 2026-08-04 |
| Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib - Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2007-12-17 | 2020-12-03 |
| Papillary Serous Carcinoma of the Endometrium Paclitaxel, Pelvic Radiation, Dexamethasone - Endometrial Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 30 | 2001-04-01 | 2014-07-03 |
Cystadenocarcinoma, Serous (11) · Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Adenocarcinoma, Mucinous (2) · Carcinosarcoma (2) · Fallopian Tube Neoplasms (2) · Vulvar Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adrenocortical Carcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1)
Adenocarcinoma (11) · Carcinoma (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Neoplasms, Cystic, Mucinous, and Serous (11) · Neoplasms, Glandular and Epithelial (11) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Neoplasms by Site (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7)
Letrozole (2) · Paclitaxel (2) · niraparib (2) · AZD 6244 (1) · Axitinib (1) · CTLA-4 Antigen (1) · Cimetidine (1) · Dexamethasone (1) · Diphenhydramine (1) · Doxorubicin (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Specimen Handling (1) · Tamoxifen (1)
National Cancer Institute (NCI) (3) · Blokhin's Russian Cancer Research Center (1) · Gynecologic Oncology Group (1) · Incyte Corporation (1) · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (1) · M.D. Anderson Cancer Center (1) · North Eastern German Society of Gynaecological Oncology (1) · Shandong University (1) · University Health Network, Toronto (1)
United States (6) · Canada (2) · United Kingdom (2) · Australia (1) · China (1) · Georgia (1) · Germany (1) · Guam (1) · Russia (1)
Amit Oza, MD (1) · Anuja Jhingran, MD (1) · Brian Slomovitz, MD (1) · David M Gershenson (1) · John H Farley (1) · Philomena Colucci (1) · Sandip P Patel (1)
PMID 23261356, PMID 23385150, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 35123694, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41108824, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
U10CA180868 (2), 2023 (1), P50CA083639 (1), U10CA027469 (1), U10CA180888 (1)